Johnson & Johnson said it will invest more than $1 billion to build a cell therapy manufacturing facility in Montgomery County, Pennsylvania, expanding its domestic capacity for medicines that treat certain cancers and diseases.
The plant will support more than 500 biomanufacturing jobs when fully operational and thousands of construction jobs during site development, according to a news release.
The investment is part of J&J’s broader $55 billion commitment to advance manufacturing, research and development and technology through early 2029.
The company announced two new U.S. locations last month, including a drug product facility in Wilson, North Carolina, but provided sparse details on the projects. The second site was in rural Pennsylvania.
J&J will receive $39 million in tax credits, grants and other state incentives for its investment in Lower Gwynedd Township, Montgomery County, according to the office of Gov. Josh Shapiro.
The state is also awarding up to $2.5 million to a local community college or technical school to help create a workforce development training program and serve as a talent pipeline for the company in the area.
Janssen Biotech, a J&J subsidiary, will operate the Pennsylvania facility.
